Opaleye Management Inc. - Jan 21, 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role: 10%+ Owner
Signature: Opaleye Management Inc., By: /s/ James Silverman, President
Stock symbol: TCON
Transactions as of: Jan 21, 2022
Transactions value $: $112,414
Form type: 4
Date filed: 1/24/2022, 05:18 PM
Previous filing: Jan 21, 2022
Next filing: Jan 31, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$65.8K	+30K	+1.08%	$2.19^*	2.82M	Jan 21, 2022	By Opaleye, L.P.	F1, F3
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$11K	+5K	+1.61%	$2.19^*	315K	Jan 21, 2022	By Managed Account	F2, F3
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$30.8K	+15K	+0.53%	$2.05	2.84M	Jan 24, 2022	By Opaleye, L.P.	F1, F4
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$4.85K	+2.36K	+0.75%	$2.05	317K	Jan 24, 2022	By Managed Account	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCON	Prefunded Warrants						1.89M	Jan 21, 2022	Common Stock	1.89M	$0.01	By Opaleye,L.P.	F4, F5
holding	TCON	Prefunded Warrants						1.36M	Jan 21, 2022	Common Stock	1.36M	$0.01	By Opaleye,L.P.	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2	Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3	The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $2.1946 The range of purchase prices on the transaction date was $2.16 to $2.22 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F4	The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $2.0505 The range of purchase prices on the transaction date was $2.015 to $2.20 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F5	The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 9.99% of the issuers then outstanding shares.